Lauren Feldman 9/01/2023 at 4:01 pm
Cosmos (August 31, 2023) Library of mini organs reducing the need for animal testing
CSIRO researchers have teamed up with the Lyell McEwin Hospital in Adelaide to create a library of organoids, or mini organs, to advance the prevention, diagnosis and treatment of colorectal cancers.
Cosmos (August 31, 2023) As world shifts to non-animal testing CSIRO outlines opportunities for Australia
The CSIRO says Australia has 5 years to maximize the economic and scientific opportunities on offer as part of the global shift to non-animal models in medical research. With the use of animals in medical product development expected to decline, there is a risk to existing clinical industries if the country doesn’t keep pace with international trends.
Techcrunch (August 30, 2023) QuantHealth brings its AI-informed clinical drug trials to the US with $15M round
Biotech, pharmaceutical and life sciences companies all hope AI will streamline drug development and make it more efficient, and 38% have already adopted the technology, according to Deloitte. QuantHealth aims to take part with a model that predicts risks and outcomes for clinical trials. The company’s AI-powered platform for drug discovery claims to reduce potential risks, optimize clinical trials and help identify how patients in a clinical trial would respond to treatment. The Tel Aviv-based startup said Wednesday it had raised a $15 million Series A funding round, which brings its total raised to $20 million.
Science Daily (August 30, 2023) AI enabled soft robotic implant monitors scar tissue to self-adapt for personalized drug treatment
Research teams have detailed a pioneering breakthrough in medical device technology that could lead to intelligent, long-lasting, tailored treatment for patients, thanks to soft robotics and artificial intelligence.
MedCityNews (August 30, 2023) The Inflation Reduction Act’s Impact on Drug Development for Rare Diseases
Despite these wins for many patients, the new law is already impacting the discovery and development of new drugs for people living with orphan diseases. Not only are drugs that could treat more than one disease being disincentivized, small molecule medicines, which play an important role in treating neurological disorders, cancers, and other diseases, may also be disadvantaged by the law.
Technology Networks (August 29,2023) Man’s Best Friend – Solving the Dog Epigenome To Advance Human Oncology
The field of human cancer research has been transformed by the wealth of next-generation sequencing (NGS) data, but veterinary medicine lacks an equivalent volume of canine-specific data. To bridge this gap, the Cho Lab at the College of Veterinary Medicine, Seoul National University, has undertaken pioneering work in mapping the epigenome of the domesticated dog.1 This work comprises epigenomic studies that examine the chemical modifications to DNA and histone proteins that can influence gene expression, shedding light on the regulation of cancer-related genes. The research is helping to unlock valuable information to progress our understanding of comparative oncology by expanding the availability of canine NGS datasets, and this data is now being employed to investigate cancer biology using organoids.
Boston Globe (August 29, 2023) Ginkgo Bioworks partnering with Google for AI-based drug discovery
Diving headfirst into the generative artificial intelligence market, Ginkgo Bioworks said on Tuesday it plans to develop its own AI models for drug development and other synthetic biology applications. Creating an AI model like the one underlying ChatGPT, but specialized for drug discovery, will require a vast amount of computing power. So, Boston-based Ginkgo also announced a five-year deal with Google for access to the search giant’s cloud computing and AI modeling resources. Under a five-year agreement, Ginkgo will pay Google escalating minimum amounts for its computing and AI services, starting with $8 million in the first year and rising to $113 million by the fifth year, for a total required expenditure of $289 million, according to a securities filing. Google also agreed to provide Ginkgo with up to $56 million in funding over the next three years, dependent on Ginkgo meeting undisclosed business milestones.
News Medical & Life Sciences (August 28, 2023) Beyond traditional models: 3D bioprinted tumor microenvironment unlocks resistance insights
In a recent study published in Scientific Reports, researchers developed a three-dimensional (3D) biologically printed in vitro model of the breast cancer tumor microenvironment (TME) consisting of simultaneously cultured cells dispersed in hydrogels with a controlled design to assess tumor heterogeneity.
- You must be logged in to reply to this topic.